BalinBac Therapeutics
BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. The company started working on coronavirus drug solutions in January 2020, leveraging a team with extensive pharmaceutical industry experience to develop antiviral and antibacterial drugs quickly. Their mission includes providing life-saving drugs for COVID-19, preventing disease progression, eliminating the need for ventilators, and reducing hospital ICU burdens globally.
Industries
Nr. of Employees
small (1-50)
BalinBac Therapeutics
Products
Inhaled antiviral drug-device combination for pulmonary delivery
A series of combination products that deliver antiviral agents directly to lung/respiratory tissue using portable vaporizer or related inhalation devices to target infection sites.
Oral antiviral pill delivery system
Oral pill formulations and delivery approaches intended to complement pulmonary delivery for antiviral agents unsuitable for inhalation.
Pipeline of repurposed combination antiviral candidates
A library of approximately 20 combination candidates that pair two or more existing/generic drugs with complementary antiviral mechanisms for confirmatory clinical trials.
Inhaled antiviral drug-device combination for pulmonary delivery
A series of combination products that deliver antiviral agents directly to lung/respiratory tissue using portable vaporizer or related inhalation devices to target infection sites.
Oral antiviral pill delivery system
Oral pill formulations and delivery approaches intended to complement pulmonary delivery for antiviral agents unsuitable for inhalation.
Pipeline of repurposed combination antiviral candidates
A library of approximately 20 combination candidates that pair two or more existing/generic drugs with complementary antiviral mechanisms for confirmatory clinical trials.
Services
Advancement and management of programs that evaluate repurposed FDA-cleared or IND-approved antiviral and antibacterial agents for new respiratory indications.
Integrated development services to pair antiviral formulations with inhalation devices (portable vaporizers and other respiratory devices) for targeted lung delivery.
Advisory and project execution support for CMC development, IND enabling toxicology and safety pharmacology, regulatory submissions, and quality systems.
Advancement and management of programs that evaluate repurposed FDA-cleared or IND-approved antiviral and antibacterial agents for new respiratory indications.
Integrated development services to pair antiviral formulations with inhalation devices (portable vaporizers and other respiratory devices) for targeted lung delivery.
Advisory and project execution support for CMC development, IND enabling toxicology and safety pharmacology, regulatory submissions, and quality systems.
Expertise Areas
- Clinical trial management and clinical development
- Drug repurposing for infectious disease
- Respiratory drug delivery and inhalation systems
- Drug-device combination product development
Key Technologies
- Pulmonary inhalation delivery via portable vaporizers
- Oral pill delivery systems for antivirals
- Drug conjugates designed to decouple into active agents
- Multi-mechanism antiviral regimen design
News & Updates
Interview Beyond Confidence, with Divya Parekh, featuring John Gregg discussing Covid-19 therapeutics.
Interview Beyond Confidence, with Divya Parekh, featuring John Gregg discussing Covid-19 therapeutics.